Last reviewed · How we verify
Symbicort® forte Turbohaler®
Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Symbicort combines a long-acting beta-2 agonist (formoterol) and an inhaled corticosteroid (budesonide) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Symbicort® forte Turbohaler® |
|---|---|
| Sponsor | University Hospital, Antwerp |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) |
| Target | Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Budesonide is a corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and sustained airway opening. The combination provides both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort® forte Turbohaler® CI brief — competitive landscape report
- Symbicort® forte Turbohaler® updates RSS · CI watch RSS
- University Hospital, Antwerp portfolio CI